BIvideocpd5

Name:

Surname:

MP Number:

Email address:

Contact number:

Question 1
What is the most important goal of oral anticoagulation therapy in patients with non-valvular atrial fibrillation (NVAF)?

a) To prevent strokes and intracranial haemorrhage

b) To reduce major bleeding

c) To reduce CV mortality

d) To provide anticoagulation without increasing the risk of gastrointestinal (GI) bleeding

Question 2
What is the difference in the reduction of stroke/systemic embolism (SE) for dabigatran vs. warfarin in the RE-LY® study?

a) 15-26 %

b) 57-60 %

c) 35-37 %

d) 30 %

Question 3
What was the difference in major GI bleeding for dabigatran 150 mg vs. warfarin in the RE-LY® study in patients younger than 75 years?

a) Lower

b) No difference

c) Increased

d) Not known

Question 4
True or false? Major GI bleeding associated with dabigatran did not affect overall mortality in the RE-LY® study and is manageable.

a) True

b) False

Question 5
What was the difference in the reduction of major bleeding achieved by dabigatran vs. warfarin in the RE-LY® study?

a) 15-26 %

b) 57-60 %

c) 35-37 %

d) 20-30 %

Question 6
True or false: GI bleeding from anticoagulation can show up underlying pathology in the bowel that would not be known otherwise.

a) True

b) False

Question 7
How does the reduction in stroke/SE with dabigatran and rivaroxaban vs. warfarin compare in patients < 75 years in the RE-LY® and ROCKET-AF studies respectively?

a) Greater reduction with both

b) Greater reduction with rivaroxaban

c) Greater reduction with dabigatran

d) Similar reduction compared to warfarin

Question 8
True or false: The RE-LY® study shows that the risk of GI bleeding in elderly patients treated with dabigatran 110 mg is similar vs. warfarin

a) True

b) False

Question 9
Which statement regarding bleeding with dabigatran is correct?

a) GI bleeding is more manageable with dabigatran than warfarin

b) b) GI bleeding with dabigatran is no different vs. warfarin if the right dose is used in the right patient

c) c) The overall reduction in major bleeding with dabigatran vs. warfarin means that dabigatran’s benefits outweigh its side effects

d) All of the above

Question 10
In patients < 75 years in the RE-LY® study, dabigatran 150 mg showed superior efficacy vs. warfarin for:

a) CV mortality

b) Major bleeding

c) Patients with comorbidities

d) All of the above

Question 11
Which statement regarding apixaban vs. warfarin in the ARISTOTLE is incorrect?

a) Apixaban causes less GI bleeding

b) Apixaban showed a greater reduction in stroke and intracranial haemorrhage

c) Apixaban showed a greater reduction in major bleeding

d) The incidence of CV mortality was similar

Question 12
When compared to warfarin, which event occurs with a lower incidence regardless of dabigatran dose or patient age?

a) Major bleeding

b) Intracranial haemorrhage

c) Major extracranial bleeding

d) All of the above